Showing results (1631-1640 of 1,707) with videos related to

Sort By:
Pageof 171
BMC Veterinary Research|May 19, 2026
Epidemiological and genetic variation analysis of emerging porcine circovirus type 3 in Henan Province, 2023-2024Jiajing Song, Hongyue Zhai, Jiajia Cao, et al.
Plos One|July 22, 2015
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective StudiesDandan Li, Li Wang, Honghu Zhu, et al.
Medcomm|February 19, 2025
Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAFV600-mutant advanced melanoma: a multicenter cohort studyJunwan Wu, Qiuyue Ding, Qiong Zhang, et al.
Frontiers in Aging Neuroscience|October 26, 2018
Increased Functional Brain Network Efficiency During Audiovisual Temporal Asynchrony Integration Task in AgingBin Wang, Peizhen Li, Dandan Li, et al.
Plos One|April 11, 2013
Novel DNA variants and mutation frequencies of hMLH1 and hMSH2 genes in colorectal cancer in the Northeast China populationFulan Hu, Dandan Li, Yibaina Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapyLujun Shen, Hongtong Tan, Juan Nie, et al.
Molecular Cancer Therapeutics|June 10, 2024
A Selective FGFR1/2 PROTAC Degrader with Antitumor ActivityYing Kong, Xinyue Zhao, Zhaofu Wang, et al.
Vaccines|February 24, 2024
Heterologous Booster Immunization Based on Inactivated SARS-CoV-2 Vaccine Enhances Humoral Immunity and Promotes BCR Repertoire DevelopmentXinghang Li, Fengyuan Zeng, Rong Yue, et al.
Frontiers in Oncology|February 26, 2024
An immune-related gene prognostic prediction risk model for neoadjuvant chemoradiotherapy in rectal cancer using artificial intelligencePei Shu, Ning Liu, Xu Luo, et al.
Molecular Cancer Therapeutics|April 22, 2024
A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activityYing Kong, Xinyue Zhao, Zhaofu Wang, et al.
Pageof 171